Automated Testing For Compound Toxicity Effects Using Healthy Intestinal Organoids

By Oksana Sirenko and Krishna Macha, Molecular Devices

This content is brought to you by Molecular Devices, a Danaher Operating Company.

Anti-cancer drugs often have significant side effects, with one of the most common being their toxic impact on intestinal cells. This toxicity frequently limits the dosage that can be safely administered to patients, thereby affecting the overall effectiveness of the treatment. To address this issue, researchers utilize in vitro assays with three-dimensional (3D) organoids to evaluate the toxicity effects on the intestine. These 3D organoids mimic the structure and function of actual intestinal tissues to provide crucial insights during the drug development process.

Examine how automation not only speeds up the testing process but also improves the accuracy of assays involving complex 3D biological structures. This advancement is essential for efficiently developing safer and more effective anti-cancer drugs.